Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:MRNS

Marinus Pharmaceuticals (MRNS) Stock Price, News & Analysis

Marinus Pharmaceuticals logo

About Marinus Pharmaceuticals Stock (NASDAQ:MRNS)

Advanced Chart

Key Stats

Today's Range
$0.55
$0.55
50-Day Range
$0.55
$0.55
52-Week Range
$0.22
$1.97
Volume
260 shs
Average Volume
1.94 million shs
Market Capitalization
$30.32 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.92
Consensus Rating
Hold

Company Overview

Marinus Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
53rd Percentile Overall Score

MRNS MarketRank™: 

Marinus Pharmaceuticals scored higher than 53% of companies evaluated by MarketBeat, and ranked 486th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Marinus Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.44, and is based on 2 buy ratings, 6 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Marinus Pharmaceuticals has received no research coverage in the past 90 days.

  • Read more about Marinus Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Marinus Pharmaceuticals are expected to grow in the coming year, from ($1.99) to ($0.49) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Marinus Pharmaceuticals is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Marinus Pharmaceuticals is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Marinus Pharmaceuticals has a P/B Ratio of 1.77. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for MRNS.
  • Dividend Yield

    Marinus Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Marinus Pharmaceuticals does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for MRNS.
    • Insider Buying vs. Insider Selling

      In the past three months, Marinus Pharmaceuticals insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      Only 5.46% of the stock of Marinus Pharmaceuticals is held by insiders.

    • Percentage Held by Institutions

      98.80% of the stock of Marinus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

    • Read more about Marinus Pharmaceuticals' insider trading history.
    Receive MRNS Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Marinus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

    By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

    MRNS Stock News Headlines

    A Major Economic Change Is Happening Now
    Louis Navellier is one of Wall Street’s most respected money managers — overseeing more than $7 billion and earning a reputation for fact-based analysis, not sensationalism. That’s why his latest economic warning is turning so many heads. In his new report, Louis reveals how recent policies are accelerating a massive economic shift. While headlines point to strong numbers, everyday Americans feel the squeeze as prices climb and industries are reshaped. According to Louis, this transformation could determine who falls behind — and who builds lasting wealth.tc pixel
    See More Headlines

    MRNS Stock Analysis - Frequently Asked Questions

    Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) announced its quarterly earnings results on Tuesday, August, 13th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.59) by $0.01. The biopharmaceutical company had revenue of $8.06 million for the quarter, compared to analysts' expectations of $9.05 million. Marinus Pharmaceuticals had a negative trailing twelve-month return on equity of 7,831.35% and a negative net margin of 446.48%.
    Read the conference call transcript
    .

    Shares of Marinus Pharmaceuticals reverse split before market open on Wednesday, September 23rd 2020.The 1-4 reverse split was announced on Tuesday, September 22nd 2020. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 22nd 2020. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

    Based on aggregate information from My MarketBeat watchlists, some other companies that Marinus Pharmaceuticals investors own include Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), DiamondRock Hospitality (DRH), American Water Works (AWK), AU Optronics (AUOTY) and Triple Flag Precious Metals (TFPM).

    Company Calendar

    Last Earnings
    8/13/2024
    Today
    8/26/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    Pharmaceutical preparations
    Sub-Industry
    Pharmaceutical Products
    Current Symbol
    NASDAQ:MRNS
    CIK
    1267813
    Employees
    110
    Year Founded
    N/A

    Price Target and Rating

    High Price Target
    $10.00
    Low Price Target
    $0.50
    Potential Upside/Downside
    +613.3%
    Consensus Rating
    Hold
    Rating Score (0-4)
    2.44
    Research Coverage
    9 Analysts

    Profitability

    EPS (Trailing Twelve Months)
    ($2.47)
    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    -$141.40 million
    Net Margins
    -446.48%
    Pretax Margin
    -446.48%
    Return on Equity
    -7,831.35%
    Return on Assets
    -120.74%

    Debt

    Debt-to-Equity Ratio
    N/A
    Current Ratio
    1.66
    Quick Ratio
    1.47

    Sales & Book Value

    Annual Sales
    $30.99 million
    Price / Sales
    0.98
    Cash Flow
    N/A
    Price / Cash Flow
    N/A
    Book Value
    $0.31 per share
    Price / Book
    1.77

    Miscellaneous

    Outstanding Shares
    55,220,000
    Free Float
    52,203,000
    Market Cap
    $30.32 million
    Optionable
    Optionable
    Beta
    1.03

    Social Links

    7 Stocks to Ride The A.I. Megaboom Cover


    We are about to experience the greatest A.I. boom in stock market history...

    Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

    That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

    1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
    2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
    3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

    Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

    And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

    Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

    Get This Free Report

    This page (NASDAQ:MRNS) was last updated on 8/26/2025 by MarketBeat.com Staff
    From Our Partners